...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut
【24h】

Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

机译:粪便耐药急性移植患者患者的粪便微生物会移植 - 肠道

获取原文
获取原文并翻译 | 示例
           

摘要

Increasing evidence indicates that the gut microbiota is closely associated with acute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immunosuppressed status. We therefore conducted a pilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n = 3) or steroid-dependent gut aGVHD (n = 1) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD. This trial was registered at the University Hospital Medical Information Network (https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000017575) as #UMIN000015115.
机译:越来越多的证据表明,肠道微生物已与干细胞移植(SCT)中的急性接枝腹膜疾病(AGVHD)密切相关。 FECAL Microbiota移植(FMT)可以代表AGVHD的替代治疗选择。然而,由于严重免疫抑制状态,SCT患者的FMT患有感染的微生物群潜在的感染风险。因此,我们进行了试点研究,以评估SCT中FMT的安全性。共有4例抗类固醇(n = 3)或类固醇依赖性肠道agvhd(n = 1)接受FMT。没有观察到FMT的严重不良事件。所有患者均对FMT作出反应,3个完全应答和1个部分反应。 Microbiota的时间动态似乎与患者的肠道状况相关联,周边效应器调节T细胞在对FMT的响应期间也增加。 FMT在患者中安全地进行,并可为AGVHD提供新的治疗选择。该试验已在大学医疗信息网络(https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=r000017575)作为#umin000015115。

著录项

  • 来源
  • 作者单位

    Komagome Hosp Tokyo Metropolitan Canc &

    Infect Dis Ctr Div Hematol Tokyo Japan;

    Natl Canc Ctr Div Canc Immunol Exploratory Oncol Res &

    Clin Trial Ctr Chiba Japan;

    Univ Tokyo Grad Sch Frontier Sci Chiba Japan;

    Komagome Hosp Tokyo Metropolitan Canc &

    Infect Dis Ctr Div Hematol Tokyo Japan;

    Komagome Hosp Tokyo Metropolitan Canc &

    Infect Dis Ctr Div Gastroenterol Tokyo Japan;

    RIKEN Ctr Integrat Med Sci Yokohama Kanagawa Japan;

    Okayama Univ Grad Sch Environm &

    Life Sci Okayama Japan;

    Okayama Univ Grad Sch Environm &

    Life Sci Okayama Japan;

    Natl Canc Ctr Div Canc Immunol Exploratory Oncol Res &

    Clin Trial Ctr Chiba Japan;

    Natl Canc Ctr Div Canc Immunol Exploratory Oncol Res &

    Clin Trial Ctr Chiba Japan;

    Univ Tokyo Grad Sch Frontier Sci Chiba Japan;

    Komagome Hosp Tokyo Metropolitan Canc &

    Infect Dis Ctr Div Hematol Tokyo Japan;

    Komagome Hosp Tokyo Metropolitan Canc &

    Infect Dis Ctr Div Hematol Tokyo Japan;

    Komagome Hosp Tokyo Metropolitan Canc &

    Infect Dis Ctr Div Hematol Tokyo Japan;

    Univ Tokyo Dept Hematol &

    Oncol Fac Med Tokyo Japan;

    Komagome Hosp Tokyo Metropolitan Canc &

    Infect Dis Ctr Div Hematol Tokyo Japan;

    Komagome Hosp Tokyo Metropolitan Canc &

    Infect Dis Ctr Div Gastroenterol Tokyo Japan;

    Keio Univ Dept Microbiol &

    Immunol Sch Med Tokyo Japan;

    Komagome Hosp Tokyo Metropolitan Canc &

    Infect Dis Ctr Div Hematol Tokyo Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 血液及淋巴系疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号